Abstract
Introduction
With the pharmaceutical industry reducing its focus on the primary care
blockbuster model, Big Pharma is now looking towards the development and
commercialization of more niche, high value, often biologic therapies, for the
treatment of smaller patient populations.
Scope of this research
- Provides an overview of orphan drugs, including drivers and resistors of
investing in this niche market
- Examines orphan drug developmental and approval trends
- Analyzes Big Pharma' s attraction towards orphan drugs, supplemented with
future forecast analysis
- Assesses the future size and growth of the orphan drugs market
Research and analysis highlights
Few markets have implemented robust orphan drug policies with the exception of
the US, Europe, Japan, Australia and Singapore. Nevertheless, a number of key
emerging markets have instigated partial orphan drug policies which are
anticipated to be strengthened in the near future.
With increasing cost pressures facing payers, combined with the growing number
of orphan drugs now on the market and in development, measures aimed at
reducing costs can be expected by shifting payment onto the patient or even
the pharma companies themselves through risk-sharing agreements.
Oncology is the most frequently investigated therapy area, with nearly half of
all pipeline orphan drugs designated for such indications. However, with the
availability of marketed products for a number of the most frequently targeted
orphan indications, competition in these areas is set to grow.
Key reasons to purchase this research
- Gain insight into the challenges companies face when developing and
commercializing orphan drugs.
- Examine which are the most popular orphan indications, and the most
dominant orphan drug players in the market.
- Identify strategies to maximize the commercial opportunities of orphan
drugs through both revenue expansion and protection.
| 
View Cart
